Literature DB >> 15711975

Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

T J H Volman1, R J A Goris, T Hendriks.   

Abstract

OBJECTIVE: To investigate the effects of pentoxifylline (PTX) administration in a murine model for the multiple-organ dysfunction syndrome (MODS). DESIGN AND
SETTING: Prospective double-blind randomized animal study in a university research laboratory. INTERVENTIONS AND MEASUREMENTS: Sixty C57BL/6 mice were given an aseptic intraperitoneal injection of lipopolysaccharide followed after 6 days by zymosan (day 0) at a dose of either 0.9 or 1.0 mg/g body weight. Starting on day 0 mice were administered PTX at a dose of 80 mg/kg body weight or saline per os every 8 h. On day 17 surviving animals were killed, and their liver, lungs, spleen, and kidneys were collected.
RESULTS: Mortality, course of body temperature, body weight, and macroscopic lung damage were similar between zymosan-treated groups. Administration of PTX did not significantly alter survival, body temperature, body weight, or macroscopic lung damage. In addition, there were no significant differences in organ weights between mice that received PTX and mice that received PBS. Although PTX inhibited the lipopolysaccharide-induced increase in tumor necrosis factor alpha and interleukin 6 expression (but not interleukin 1beta expression) at both mRNA and protein level in a murine macrophage cell line, tumor necrosis factor alpha mRNA expression in the livers of PTX-treated mice was not significantly inhibited.
CONCLUSIONS: The results reported here do not support the hypothesis that PTX improves outcome in zymosan-induced multiple-organ dysfunction in mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711975     DOI: 10.1007/s00134-005-2570-z

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  41 in total

1.  The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo.

Authors:  E Beshay; F Croze; G J Prud'homme
Journal:  Clin Immunol       Date:  2001-02       Impact factor: 3.969

2.  Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study.

Authors:  K H Staubach; J Schröder; F Stüber; K Gehrke; E Traumann; P Zabel
Journal:  Arch Surg       Date:  1998-01

3.  The differential effect of pentoxifylline on cytokine production by alveolar macrophages and its clinical implications.

Authors:  N Poulakis; G Androutsos; D Kazi; A Bastas; A Provata; C Bitsakou; T Kontozoglou; C Polyzogopoulou; A Tassiopoulou
Journal:  Respir Med       Date:  1999-01       Impact factor: 3.415

4.  Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model.

Authors:  D Tighe; R Moss; J Hynd; S Boghossian; N al-Saady; M F Heath; E D Bennett
Journal:  Crit Care Med       Date:  1990-02       Impact factor: 7.598

5.  Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase.

Authors:  Thomas J H Volman; R Jan A Goris; Michel van der Jagt; Fons A J van de Loo; Thijs Hendriks
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

6.  A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome.

Authors:  M J Jansen; T Hendriks; R Hermsen; J W Van der Meer; R J Goris
Journal:  Cytokine       Date:  1998-11       Impact factor: 3.861

7.  Pentoxifylline prevents murine cerebral malaria.

Authors:  P G Kremsner; H Grundmann; S Neifer; K Sliwa; G Sahlmüller; B Hegenscheid; U Bienzle
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

8.  The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.

Authors:  G A DeVault; D E Kohan; E W Nelson; J M Holman
Journal:  Transplantation       Date:  1994-02-27       Impact factor: 4.939

9.  Effect of pentoxifylline on the course of systemic Candida albicans infection in mice.

Authors:  A Louie; A L Baltch; M A Franke; W J Ritz; R P Smith; J K Singh; M A Gordon
Journal:  J Antimicrob Chemother       Date:  1996-05       Impact factor: 5.790

10.  Extrinsic allergic alveolitis: inhibitory effects of pentoxifylline on cytokine production by alveolar macrophages.

Authors:  Zhaohui Tong; Baomin Chen; Huaping Dai; Peter C Bauer; Josune Guzman; Ulrich Costabel
Journal:  Ann Allergy Asthma Immunol       Date:  2004-02       Impact factor: 6.347

View more
  2 in total

1.  Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?

Authors:  John C Marshall
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

Review 2.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.